BGB-B167

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameBGB-B167
Drug Alias NameBGB-B167
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 9Anti-CEACAM5
TargetsTumor necrosis factor receptor superfamily member 9Carcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdBeOne Medicines Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A